Skip to main content

Table 1 Demographic data, clinical features, and outcomes of patients with Acinetobacter ursingii and Acinetobacter baumannii bacteremia

From: A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii

 

Acinetobacter ursingii (n = 16)

Acinetobacter baumannii (n = 252)

p value

 

n (%)/median (Q1-Q3)/mean ± S.D.

 

Gender, male

7 (43.8 %)

183 (72.6 %)

0.01

Age in years (median, IQR)

66.6 (50.0–83.2)

68.7 (52.6–84.9)

0.61

Source

Respiratory tract

4 (25 %)

130 (51.6 %)

0.04

Intra-abdominal

1 (6.25 %)

18 (7.1 %)

0.89

Urinary tract

0

19 (7.5 %)

0.25

Intravenous device

0

12 (4.8 %)

0.37

Wound

0

10 (4.0 %)

0.42

Other

1 (6.25 %)

13 (5.2 %)

0.85

Unknown

10 (62.5 %)

50 (19.8 %)

<0.01

Comorbidity

Diabetes mellitus

2 (12.5 %)

66 (26.2 %)

0.22

Hypertension

7 (43.8 %)

78 (31.0 %)

0.29

Coronary artery disease

2 (12.5 %)

30 (11.9 %)

0.94

Congestive heart failure

3 (18.8 %)

21 (8.3 %)

0.16

Chronic obstructive pulmonary disease

2 (12.5 %)

40 (15.9 %)

0.72

Cerebral vascular disease

2 (12.5 %)

47 (18.7 %)

0.54

Chronic kidney disease

3 (18.8 %)

47 (18.7 %)

0.99

End stage renal disease

1 (6.3 %)

11 (4.4 %)

0.72

Alcoholism

1 (6.3 %)

22 (8.7 %)

0.73

Malignancy

12 (75 %)

88 (34.9 %)

<0.01

Solid malignancy

7 (43.8 %)

69 (27.4 %)

0.16

Hematologic malignancy

5 (31.3 %)

19 (7.5 %)

<0.01

Neutropenia

4 (25.0 %)

9 (3.6 %)

<0.01

Trauma

0

8 (3.2 %)

0.47

Surgery in 1 month

4 (25 %)

88 (34.92 %)

0.42

Procedure

Ventilator

4 (25 %)

137 (54.4 %)

0.02

Endotracheal tube or tracheostomy

4 (25 %)

187 (74.2 %)

<0.01

Central venous catheter

6 (37.5 %)

130(51.6 %)

0.27

Artery line

6 (37.5 %)

52 (20.6 %

0.26

Foley catheter

6 (37.5 %)

157 (62.3 %)

0.05

Nasogastric tube

6 (37.5 %)

180 (71.4 %)

<0.01

Thoracic drain

0

9 (3.6 %)

0.44

Hemodialysis

1 (6.25 %)

16 (6.35 %)

0.99

Total parental nutrition

1 (6.25 %)

24 (9.5 %)

0.66

Other

Chemotherapy

9 (56.3 %)

28 (11.1 %)

<0.01

Steroid use

3 (18.8 %)

69 (27.4 %)

0.45

Shock

2 (12.5 %)

54 (21.4 %)

0.39

Acquired in ICU

3 (18.8 %)

160 (63.5 %)

<0.01

APACHE II score (median, IQR)

17.1 (10.0–24.7)

24.9 (14.6–35.1)

<0.01

Appropriate antimicrobial therapy

10 (62.5 %)

128 (50.8 %)

0.36

Hospitalized days (median, IQR)

28 (13–60)

39 (18–73.5)

0.56

Mortality

14-day mortality

1 (6.25 %)

75 (29.8 %)

0.04

28-day mortality

1 (6.25 %)

94 (37.3 %)

0.02

  1. The data were presented in number and percentage, unless indicated otherwise. IQR interquartile range, ICU intensive care unit, APACHE II Acute Physiology and Chronic Health Evaluation II
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us